P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACUTE MYELOID LEUKEMIA

Bibliographic Details
Main Authors:	N. G. Daver, P. Vyas, M. P. Chao, G. Xing, C. Renard, G. Ramsingh, D. A. Sallman, A. H. Wei
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845092.62208.b7

A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia
by: Daver, N, et al.
Published: (2021)

A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia
by: Daver, N, et al.
Published: (2022)

P550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE-3)
by: N. G. Daver, et al.
Published: (2022-06-01)

A phase 3, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy (ENHANCE-3)
by: Daver, N, et al.
Published: (2022)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
by: N. G. Daver, et al.
Published: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
by: Daver, N, et al.
Published: (2022)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results
by: Daver, NG, et al.
Published: (2022)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)
by: Vyas, P, et al.
Published: (2022)

A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia
by: Vyas, P, et al.
Published: (2021)

P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA
by: P. Vyas, et al.
Published: (2022-06-01)

Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results
by: Sallman, DA, et al.
Published: (2022)

P552: TREATMENT OUTCOMES IN NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
by: N. G. Daver, et al.
Published: (2022-06-01)

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
by: D. A. Sallman, et al.
Published: (2022-06-01)

MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
by: Sallman, D, et al.
Published: (2022)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
by: N. Daver, et al.
Published: (2022-06-01)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
by: Daver, NG, et al.
Published: (2022)

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results
by: Sallman, D, et al.
Published: (2021)

P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)
by: J. Y. Chen, et al.
Published: (2022-06-01)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
by: Chen, J, et al.
Published: (2022)

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
by: Naval G. Daver, et al.
Published: (2023-03-01)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
by: Thomas Cluzeau, et al.
Published: (2021-09-01)

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab
by: Fadi Haddad, et al.
Published: (2021-05-01)

TP53 Mutant Acute Myeloid Leukemia: The Immune and Metabolic Perspective
by: Federico Zingarelli, et al.
Published: (2022-11-01)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
by: Leiming Xia, et al.
Published: (2023-05-01)

A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
by: Sekeres, MA, et al.
Published: (2022)

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
by: Alice Mims, et al.
Published: (2023-08-01)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
by: Diego A Pereira-Martins, et al.
Published: (2023-08-01)

Regulators of Oncogenic Mutant TP53 Gain of Function
by: Satomi Yamamoto, et al.
Published: (2018-12-01)

PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
by: Naval Daver, et al.
Published: (2023-08-01)

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
by: DiNardo, CD, et al.
Published: (2020)

TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2023-06-01)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
by: Amer M. Zeidan, et al.
Published: (2023-08-01)

Inhibition of TP53 Mutant Oral Cancer by Reactivating p53
by: Yei-Jin Kang, et al.
Published: (2022-06-01)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
by: Ramy Rahmé, et al.
Published: (2023-04-01)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
by: Sayantanee Dutta, et al.
Published: (2020-03-01)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
by: Stephen L. Abrams, et al.
Published: (2022-02-01)

P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACUTE MYELOID LEUKEMIA

Similar Items

Similar Items